Pedro Folegatti
Recent publications
-
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
Journal article
Folegatti PM. et al, (2020), The Lancet, 396, 467 - 478
-
Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial
Journal article
Folegatti PM. et al, (2020), The Lancet Infectious Diseases, 20, 816 - 826
-
Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial.
Journal article
Folegatti PM. et al, (2020), The Lancet. Infectious diseases, 20, 816 - 826
-
Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial (vol 20, pg 816, 2020)
Journal article
Folegatti PM. et al, (2020), LANCET INFECTIOUS DISEASES, 20, 148 - 148
-
Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial (vol 23, pg 861, 2020)
Journal article
Folegatti PM. et al, (2020), LANCET INFECTIOUS DISEASES, 20, 148 - 148